Drug Profile
NB 325
Alternative Names: NB-325Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Nexgen Biosciences
- Class Glycopeptides; Peptide antibiotics
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Bacterial infections in USA (unspecified route) (Nexgen Biosciences pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 05 Aug 2016 Preclinical trials in Bacterial infections in USA (unspecified route)